Currently submitted to: JMIR Cancer
Date Submitted: Jan 20, 2026
Open Peer Review Period: Jan 23, 2026 - Mar 20, 2026
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Explainable Machine Learning Based Prediction of Progression-Free Survival in Prostate Cancer: A Retrospective Cohort Study
ABSTRACT
Background:
Progression-free survival (PFS) is a critical endpoint in oncology, yet real-world applications of individualised, explainable machine-learning (ML) predictions remain limited.
Objective:
This study aims to develop and validate explainable ML models to predict PFS using retrospective data from a national prostate cancer cohort in Brunei Darussalam.
Methods:
We analysed a retrospective cohort of 212 patients (478 longitudinal observations) treated at the Brunei Cancer Centre (January 2018 to December 2024). Clinical, laboratory, and treatment data were harmonised, with missing values imputed via Extremely Randomised Trees. Longitudinal patterns were captured using a recurrent autoencoder to generate latent representations. We compared four modelling approaches: Cox Proportional Hazards (CPH), Random Survival Forests (RSF), Gradient Boosting Survival (GBS), and Deep Neural Network Survival models. Performance was evaluated using time-dependent AUC, Harrell’s C-index, and Integrated Brier Score (IBS), with SHAP (Shapley Additive exPlanations) used for interpretability.
Results:
RSF demonstrated improved discriminative performance and balanced calibration, achieving a C-index of 0.906 and AUCs of 0.941 at both 4 and 5 years (IBS = 0.0698). In contrast, the traditional CPH model performed poorly (C-index 0.531; AUC 0.706 at 4 years). Deep survival (AUCs of 0.941 at 4 years and 0.941 at 5 years, C-index 0.719, IBS=0.0590) and GBS (AUCs of 0.765 at 4 years and 0.833 at 5 years, C-index 0.844, IBS=0.0887) models showed moderate performance. SHAP analysis identified sodium (Na), alanine aminotransferase (ALT), MCH, platelet count, and specific treatment categories as key drivers of increased progression risk.
Conclusions:
Tree-based ensemble approaches, particularly RSF integrated with SHAP, offer high accuracy for personalised risk stratification in prostate cancer. These findings highlight the potential of explainable ML to enhance clinical decision-making. However, external validation in larger multi-institutional, multi-omics dataset is required before routine clinical implementation.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.